Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Akers Biosciences (AKER) Competitors

Akers Biosciences logo

AKER vs. MYMD, NAVB, VNRX, SBFM, SLXN, INAB, AIM, EVGN, LUCY, and TCRT

Should you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), VolitionRx (VNRX), Sunshine Biopharma (SBFM), Silexion Therapeutics (SLXN), IN8bio (INAB), AIM ImmunoTech (AIM), Evogene (EVGN), Innovative Eyewear (LUCY), and Alaunos Therapeutics (TCRT). These companies are all part of the "medical" sector.

Akers Biosciences vs. Its Competitors

Akers Biosciences (NASDAQ:AKER) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Akers Biosciences Neutral
MyMD Pharmaceuticals Neutral

5.5% of Akers Biosciences shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 0.3% of Akers Biosciences shares are held by company insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Akers Biosciences has higher revenue and earnings than MyMD Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akers Biosciences$1.58M1.00-$3.89MN/AN/A
MyMD PharmaceuticalsN/AN/A-$4MN/AN/A

Akers Biosciences has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Akers Biosciences' return on equity of -87.42% beat MyMD Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Akers BiosciencesN/A -87.42% -73.31%
MyMD Pharmaceuticals N/A -179.05%-108.14%

Summary

Akers Biosciences beats MyMD Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Akers Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKER vs. The Competition

MetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ Exchange
Market Cap$1.58M$18.09M$5.50B$9.40B
Dividend YieldN/AN/A3.80%4.05%
P/E RatioN/AN/A28.0819.83
Price / Sales1.0018.54433.49100.57
Price / CashN/AN/A35.8457.94
Price / Book0.020.018.135.64
Net Income-$3.89M-$15.34M$3.25B$257.88M

Akers Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKER
Akers Biosciences
N/A$0.09
-13.1%
N/A-94.3%$1.58M$1.58M0.004Gap Down
High Trading Volume
MYMD
MyMD Pharmaceuticals
N/A$0.10
-6.3%
N/A-94.3%$242KN/A0.006Gap Down
High Trading Volume
NAVB
Navidea Biopharmaceuticals
N/A$0.00
flat
N/A-90.0%$20K$8.13K0.0010
VNRX
VolitionRx
2.1395 of 5 stars
$0.65
-4.5%
$3.50
+435.3%
+3.3%$67.99M$1.31M-1.8280News Coverage
Analyst Forecast
Gap Up
SBFM
Sunshine Biopharma
3.2869 of 5 stars
$1.51
+1.2%
$15.00
+894.7%
+398.3%$6.79M$34.87M-0.013Positive News
Gap Down
SLXN
Silexion Therapeutics
N/A$0.76
-2.4%
$5.00
+557.8%
N/A$6.77MN/A0.00N/ANews Coverage
Positive News
INAB
IN8bio
3.4702 of 5 stars
$2.16
-2.7%
$180.00
+8,233.3%
-91.5%$6.72MN/A-0.1620
AIM
AIM ImmunoTech
1.4783 of 5 stars
$8.79
-4.0%
$275.00
+3,030.0%
-79.5%$6.71M$146K-18.6920Gap Down
EVGN
Evogene
2.9068 of 5 stars
$1.26
+0.8%
$3.50
+177.8%
-78.5%$6.71M$8.51M-0.47140Gap Up
LUCY
Innovative Eyewear
0.3625 of 5 stars
$2.16
+0.5%
N/A-71.3%$6.66M$1.64M-0.549
TCRT
Alaunos Therapeutics
0.6124 of 5 stars
$3.38
-15.5%
N/A-47.4%$6.56M$10K-1.3340News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:AKER) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners